Investigational Drug Information for LNP023
✉ Email this page to a colleague
What is the drug development status for LNP023?
LNP023 is an investigational drug.
There have been 21 clinical trials for LNP023.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 25th 2021.
The most common disease conditions in clinical trials are Hemoglobinuria, Paroxysmal, Hemoglobinuria, and Kidney Diseases. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].
There are two US patents protecting this investigational drug and forty-six international patents.
Summary for LNP023
| US Patents | 2 |
| International Patents | 46 |
| US Patent Applications | 17 |
| WIPO Patent Applications | 13 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2021-01-25) |
| Vendors | 29 |
Recent Clinical Trials for LNP023
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | Novartis Pharmaceuticals | Phase 3 |
| Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS | Novartis Pharmaceuticals | Phase 3 |
| Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN | Novartis Pharmaceuticals | Phase 3 |
Clinical Trial Summary for LNP023
Top disease conditions for LNP023
Top clinical trial sponsors for LNP023
US Patents for LNP023
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LNP023 | ⤷ Sign Up | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | Novartis AG | ⤷ Sign Up |
| LNP023 | ⤷ Sign Up | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | Novartis AG | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
